CN113678972A - 一种增强免疫力的组合物及其制备方法 - Google Patents
一种增强免疫力的组合物及其制备方法 Download PDFInfo
- Publication number
- CN113678972A CN113678972A CN202110762563.4A CN202110762563A CN113678972A CN 113678972 A CN113678972 A CN 113678972A CN 202110762563 A CN202110762563 A CN 202110762563A CN 113678972 A CN113678972 A CN 113678972A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- composition
- zinc
- enhancing immunity
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 229930003231 vitamin Natural products 0.000 claims abstract description 40
- 235000013343 vitamin Nutrition 0.000 claims abstract description 40
- 239000011782 vitamin Substances 0.000 claims abstract description 40
- 229940088594 vitamin Drugs 0.000 claims abstract description 40
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 27
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 27
- 235000021119 whey protein Nutrition 0.000 claims abstract description 27
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 26
- 235000010755 mineral Nutrition 0.000 claims abstract description 26
- 239000011707 mineral Substances 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims abstract description 19
- 238000007873 sieving Methods 0.000 claims abstract description 19
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 18
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 18
- 238000007710 freezing Methods 0.000 claims abstract description 14
- 230000008014 freezing Effects 0.000 claims abstract description 14
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 10
- 238000010257 thawing Methods 0.000 claims abstract description 8
- 239000004615 ingredient Substances 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- 239000011701 zinc Substances 0.000 claims description 21
- 229910052725 zinc Inorganic materials 0.000 claims description 21
- 229910052711 selenium Inorganic materials 0.000 claims description 19
- 239000011669 selenium Substances 0.000 claims description 19
- 229940091258 selenium supplement Drugs 0.000 claims description 19
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 16
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 14
- 229930003268 Vitamin C Natural products 0.000 claims description 14
- 235000019154 vitamin C Nutrition 0.000 claims description 14
- 239000011718 vitamin C Substances 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 102000010445 Lactoferrin Human genes 0.000 claims description 7
- 108010063045 Lactoferrin Proteins 0.000 claims description 7
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 7
- 229940078795 lactoferrin Drugs 0.000 claims description 7
- 235000021242 lactoferrin Nutrition 0.000 claims description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 125000003929 folic acid group Chemical group 0.000 claims description 6
- 229940001941 soy protein Drugs 0.000 claims description 6
- 239000011691 vitamin B1 Chemical group 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 5
- 239000011781 sodium selenite Substances 0.000 claims description 5
- 229960001471 sodium selenite Drugs 0.000 claims description 5
- 235000015921 sodium selenite Nutrition 0.000 claims description 5
- 239000011715 vitamin B12 Substances 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 4
- 102000008114 Selenoproteins Human genes 0.000 claims description 4
- 108010074686 Selenoproteins Proteins 0.000 claims description 4
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 4
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 4
- 239000011670 zinc gluconate Substances 0.000 claims description 4
- 235000011478 zinc gluconate Nutrition 0.000 claims description 4
- 229960000306 zinc gluconate Drugs 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- 239000011746 zinc citrate Substances 0.000 claims description 3
- 235000006076 zinc citrate Nutrition 0.000 claims description 3
- 229940068475 zinc citrate Drugs 0.000 claims description 3
- 239000011576 zinc lactate Substances 0.000 claims description 3
- 235000000193 zinc lactate Nutrition 0.000 claims description 3
- 229940050168 zinc lactate Drugs 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 229960001939 zinc chloride Drugs 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 235000018102 proteins Nutrition 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 238000012360 testing method Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 12
- 239000011521 glass Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 235000021120 animal protein Nutrition 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 206010057249 Phagocytosis Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 239000003228 hemolysin Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000008782 phagocytosis Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 231100000416 LDH assay Toxicity 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000698776 Duma Species 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 240000003394 Malpighia glabra Species 0.000 description 1
- 235000014837 Malpighia glabra Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- JIVSXRLRGOICGA-UHFFFAOYSA-N promazine hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 JIVSXRLRGOICGA-UHFFFAOYSA-N 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开一种增强免疫力的组合物及其制备方法,该组合物由浓缩乳清蛋白、维生素、矿物质和益生元组成,其重量比为(20~60):(10~30)(0.5~10):(0.1~2):(2~30)。其制备方法为包括:1)将配方量的大豆分离蛋白和浓缩乳清蛋白混合,加水溶解,在‑1~‑5℃下冻结1~5h,在室温条件下解冻;再置于‑5~‑35℃下冻结10~20h,在室温条件下解冻,干燥,粉碎过筛,备用;2)将配方量的维生素、矿物质、益生元分别过筛,备用;3)将步骤1)、2)的配料混匀,即得。本发明的组合物口感好,效果好,且冲调性好。
Description
技术领域
本发明涉及保健品技术领域,具体涉及一种增强免疫力的组合物的制备方法。
背景技术
免疫力是人体自身的防御机制,是人体识别和消灭外来侵入的任何异物(病毒、细菌等),处理衰老、损伤、死亡、变性的自身细胞以及识别和处理体内突变细胞和病毒感染细胞的能力。人体内执行这一功能的是免疫系统。
目前,国内外免疫力低下的主要人群是儿童;老年人;器官移植术后长期服用免疫抑制剂的人群;接受化疗、放疗的恶性肿瘤患者;营养缺乏引起的免疫力下降人群;经常熬夜睡眠不足的人群;生活、工作压力大的人群;以及过分依赖抗生素及滥用抗生素人群;长期吸烟人群等。据专业人士调查,目前,我国免疫力低下的人群比例约为20%。
增强免疫力的的方法主要有以下几种:全面均衡适量营养、适度劳逸、经常锻炼、戒烟限酒、心理健康等,其中最方便、快捷的方法是科学的食疗方法,科学合理的蛋白质补充是必不可少的,一方面维生素A能促进糖蛋白的合成,细胞膜表面的蛋白主要是糖蛋白,免疫球蛋白也是糖蛋白。动物蛋白中乳清蛋白含丰富的蛋氨酸,氨基酸的种类齐全配比接近人体所需要的模式,浓缩乳清蛋白还含有大量免疫球蛋白,可增强人体的免疫功能,促进矿物质吸收,调节肠道菌群平衡。当大豆蛋白与浓缩乳清蛋白合用时,能够达到互补和协同作用,使蛋白质粉更易被人体消化和吸收,更能提高其增强免疫力的保健功能。
人体是由无数细胞构成的,蛋白质是主要成分。蛋白质不仅是人类机体的主要构成物质,而且蛋白质也是构成人类体内的各类重要生命活性物质,故体内的蛋白质的种类数以千计,其中包括人类赖以生存的无数的酶类,多种作用于人体代谢活动的激素类,抵御疾病侵袭的各种免疫物质类,以及各种微量元素的载体等都主要由蛋白质构成。
实验证明,蛋白质不足可能使抗体抗原结合反应和补体浓度降低,免疫器官萎缩,T淋巴细胞尤其是辅助性淋巴细胞数量减少,吞噬细胞发生机能障碍,自然杀伤(NK)细胞对靶细胞的杀伤力下降。
我国将步入老年化社会,免疫力低下的人群会逐步上升,对增强免疫力保健食品的需求逐渐上升,以蛋白质粉为代表的增强免疫力保健食品备受消费者青睐,市场上也出现较多这类产品。中国专利文献也公开了一些宣称增强免疫力保健食品的制备方法,如CN106174598A公开了一种增强免疫力的蛋白粉,由植物蛋白、动物蛋白、磷脂以及添加剂等组成,所述蛋白粉中动物蛋白和磷脂的质量需配制成一定比例。该发明提供的蛋白粉同时包含动物蛋白和植物蛋白,提高了蛋白质种类,更利于人体吸收增强人体免疫力;同时磷脂和动物蛋白按一定比例配置,避免了动物蛋白食用过量引起的高血脂、高胆固醇等危害,无副作用、更安全方便食用。再有公开号CN109588729A公开了一种增强免疫力蛋白粉及其制备方法,由浓缩乳清蛋白、针叶樱桃粉、柠檬粉、酵母粉、牛磺酸、复合维生素、氧化锌组成。经加乙醇湿润蛋白、保温下蛋白网状结构再建、包埋维生素等工艺制得蛋白粉。上述蛋白粉中,有的配方营养素过于单一,未考虑到多种营养素的协同增效;有的配方营养素过多过全,但产品安全性和保健功能并未经严格的测试评价;有的配方蛋白质含量高但腥味较重,口感不好,消费者体验感不好。不宜开发安全、有效、稳定的保健食品,因而推广使用受到一定的限制。
发明内容
本发明所要解决的技术问题是提供一种口感好、功能完善且安全的增强免疫力的组合物及其制备方法。
本发明提供了一种增强免疫力的组合物,由大豆分离蛋白、浓缩乳清蛋白、维生素、矿物质和益生元组成,其重量比为(20~60):(10~30)(0.5~10):(0.1~2):(2~30)。
所述浓缩乳清蛋白中乳铁蛋白含量>0.05%、免疫球蛋白>3%。
所述维生素是由维生素C和维生素X组成,其中,维生素C占维生素总量的重量百分比>0.8%;所述维生素X选自叶酸、维生素B1、维生素B2、维生素B6和维生素B12中的一种或多种。
所述矿物质是由硒剂和锌剂组成,其中,锌剂占矿物质总重百分比>0.1%;所述硒剂选自亚硒酸钠、硒蛋白和富硒食用菌粉中的一种或多种;所述锌剂选自葡萄糖酸锌、乳酸锌、柠檬酸锌和氯化锌中的一种或多种。
所述益生元选自低聚木糖、低聚异麦芽糖、低聚果糖和木糖醇中的一种或多种。
本发明还提供了上述增强免疫力的组合物的制备方法,包括以下步骤:
1)将配方量的大豆分离蛋白和浓缩乳清蛋白混合,加水溶解,在-1~-5℃下冻结1~5h,在室温条件下解冻;再置于-5~-35℃下冻结10~20h,在室温条件下解冻,干燥,粉碎过筛,备用;
2)将配方量的维生素、矿物质、益生元分别过筛,备用;
3)将步骤1)、2)的配料混匀,即得。
步骤1)中,水的加入量为大豆分离蛋白和浓缩乳清蛋白总重的10~25倍。
步骤1)、2)中所述过筛为过60目筛。
与现有技术相比,本发明的组合物具有以下有益效果:
1)产品配方采用大豆分离蛋白和浓缩乳清蛋白配伍,既提升蛋白质总含量,又改善氨基酸结构,是参与免疫组织和器官构成,发挥增强免疫力的物质基础;维生素组合物、矿物质组合物通过抑制细菌、抗病毒、促进免疫细胞分化、维持免疫系统正常功能等作用,协同蛋白质发挥增强免疫力作用;益生元具有调节肠道微生态平衡、促进营养物质吸收,润肠通便等功能,能改善高蛋白质粉摄入后引起的便秘等“上火”等症状,也能通过促进益生菌增殖、减缓致病菌结合间接发挥增强免疫力功能。
2)本发明通过特殊的制备方法对大豆分离蛋白和浓缩乳清蛋白进行处理,能极大提高蛋白混合物的溶解性。
具体实施方式
以下具体实施例对本发明作进一步阐述,但不作为对本发明的限定。
实施例1
1)将20kg大豆分离蛋白和10kg浓缩乳清蛋白混合,加入300kg的水溶解,在-1~-5℃下冻结1h,在室温条件下解冻;再置于-5℃下冻结10h,在室温条件下解冻,干燥,粉碎过60目筛,备用;
所述浓缩乳清蛋白中乳铁蛋白含量>0.05%、免疫球蛋白>3%;
所述维生素是由维生素C和维生素X组成,其中,维生素C占维生素总量的重量百分比为92%;所述维生素X选自叶酸、维生素B1、维生素B2、维生素B6和维生素B12的等重量比混合物;
所述矿物质是由硒剂和锌剂组成,其中,锌剂占矿物质总重百分比为67%;所述硒剂选自亚硒酸钠;所述锌剂选自葡萄糖酸锌。
所述益生元为低聚木糖;
2)将0.5kg的维生素、0.1kg矿物质、2kg益生元分别过60目筛,备用;
3)将步骤1)、2)的配料混匀,即得。
实施例2
1)将60kg大豆分离蛋白和30kg浓缩乳清蛋白混合,加入2250kg的水溶解,在-5℃下冻结5h,在室温条件下解冻;再置于-35℃下冻结20h,在室温条件下解冻,干燥,粉碎过60目筛,备用;
所述浓缩乳清蛋白中乳铁蛋白含量>0.05%、免疫球蛋白>3%;
所述维生素是由维生素C和维生素X组成,其中,维生素C占维生素总量的重量百分比为88%;所述维生素X选自叶酸;
所述矿物质是由硒剂和锌剂组成,其中,锌剂占矿物质总重百分比0.3%;所述硒剂选自硒蛋白;所述锌剂选自乳酸锌。
所述益生元为低聚异麦芽糖;
2)将10kg的维生素、2kg矿物质、30kg益生元分别过60目筛,备用;
3)将步骤1)、2)的配料混匀,即得。
实施例3
1)将30kg大豆分离蛋白和12kg浓缩乳清蛋白混合,加入840kg的水溶解,在-2℃下冻结4h,在室温条件下解冻;再置于-25℃下冻结15h,在室温条件下解冻,干燥,粉碎过60目筛,备用;
所述浓缩乳清蛋白中乳铁蛋白含量>0.05%、免疫球蛋白>3%;
所述维生素是由维生素C和维生素X组成,其中,维生素C占维生素总量的重量百分比26%;所述维生素X选自叶酸、维生素B1、维生素B2和维生素B6,其重量比为1:2:1:2;
所述矿物质是由硒剂和锌剂组成,其中,锌剂占矿物质总重百分比90%;所述硒剂选自富硒食用菌粉;所述锌剂选自柠檬酸锌。
所述益生元为低聚果糖;
2)将5kg的维生素、0.5kg矿物质、15kg益生元分别过60目筛,备用;
3)将步骤1)、2)的配料混匀,即得。
实施例4
1)将60kg大豆分离蛋白和10kg浓缩乳清蛋白混合,加入700kg的水溶解,在-5℃下冻结1h,在室温条件下解冻;再置于-35℃下冻结10h,在室温条件下解冻,干燥,粉碎过60目筛,备用;
所述浓缩乳清蛋白中乳铁蛋白含量>0.05%、免疫球蛋白>3%;
所述维生素是由维生素C和维生素X组成,其中,维生素C占维生素总量的重量百分比0.9%;所述维生素X选自维生素B1、维生素B2、维生素B6和维生素B12,其重量比为1:1:1:3;
所述矿物质是由硒剂和锌剂组成,其中,锌剂占矿物质总重百分比0.15%;所述硒剂选自亚硒酸钠、硒蛋白和富硒食用菌粉的混合物,其重量比为1:1:1;所述锌剂选自氯化锌。
所述益生元选自木糖醇;
2)将10kg的维生素、0.1kg矿物质、2kg益生元分别过60目筛,备用;
3)将步骤1)、2)的配料混匀,即得。
对照例1
1)将20kg大豆分离蛋白和10kg浓缩乳清蛋白混合,干燥,粉碎过60目筛,备用;
所述浓缩乳清蛋白中乳铁蛋白含量>0.05%、免疫球蛋白>3%;
所述维生素是由维生素C和维生素X组成,其中,维生素C占维生素总量的重量百分比为92%;所述维生素X选自叶酸、维生素B1、维生素B2、维生素B6和维生素B12的等重量比混合物;
所述矿物质是由硒剂和锌剂组成,其中,锌剂占矿物质总重百分比为67%;所述硒剂选自亚硒酸钠;所述锌剂选自葡萄糖酸锌。
所述益生元为低聚木糖;
实验例1
本发明所述增强免疫力的组合物经动物试验证明,具有增强免疫力保健作用,且无毒副作用,其详细说明如下:
1、材料与方法
1.1样品:实施例1制得的产品,临用前用蒸馏水配至所需浓度。
1.2实验动物:雄性健康SD小鼠,体重18-22g,。实验期间全部动物给予清洁级全价鼠颗粒饲料和灭菌水自由食用。
1.3实验方法:该样品成人推荐用量为12g/d,即0.2g/kg BW/d(成人体重以60kg计)。动物按体重分成四大组。分别为免疫一组:空斑、溶血素测定、脏器指数、小鼠腹腔巨噬细胞吞噬鸡红细胞试验:免疫二组:NK活性、淋转试验:免疫三组:DTH试验;免疫四组:小鼠碳廊清试验。每大组动物按体重随机分成4小组,每小组10只动物,按人日推荐量的5倍、10倍、30倍分别设1.0、2.0、6.0g/kg BW低、中、高三个剂量组和蒸馏水对照组。每组动物每天按20ml/kg BW连续灌胃30天后,分别进行以下试验。
1.3.1碳廓清实验测定:对小鼠称重,按10ml/kg BW从小鼠尾部静脉注入稀释的印度墨汁,注入墨汁后2、10min,分别从内静脉丛取血20μl,并立即将其加到2ml 0.1%Na2CO3溶液中。用722分光光度计在600nm测光密度值(OD),以Na2CO3溶液作空白对照,将小鼠处死后,解剖动物,取出肝脏、脾脏,用滤纸吸干血迹后称重,计算吞噬指数a。结果见表1。
*与对照组相比P<0.05
实验结果:样品各剂量组小鼠碳廓清吞噬指数a与对照组相比,差异均无统计学意义(P>0.05)。
1.3.2迟发型变态反应(DTH)检测:小鼠腹部皮肤用电动剃毛刀进行脱毛处理,范围约为3cm×3cm,后用DNFB溶液50μl均匀涂抹致敏;5天后,再用DNFB溶液10μl均匀涂抹于小鼠右耳两面进行攻击。24小时后劲椎脱臼处死小鼠,剪下左右两耳,用打孔器取下直径8mm的耳片称重,计算左右耳重量差值。结果见表2。
*与对照组相比P<0.05
样品高剂量组小鼠左右耳肿胀度差明显高于对照组,经统计,差异有统计学意义(P<0.05)。
1.3.3抗体生成细胞的测定:每鼠腹腔注射2%(V/V)SRBC悬液0.2ml进行免疫。5天后,摘除眼球采血做血清溶血素检测:将动物颈椎脱臼处死,取脾脏,用玻璃匀浆器磨碎,并通过四层纱布过滤,离心(1000转/10min),用Hank’S液洗两遍。将脾细胞悬浮于8mlHank’S液中。将表层培养基(1g琼脂糖加双蒸水100ml)加热溶解后,放入45℃水浴保温,与等量的PH7.2-7.4、2倍浓度的Hank’S液混合,分装小试管,每管0.5ml,再向管内加入50μl 10%SRBC、25μl脾细胞悬液,迅速混匀,倾倒于已刷琼脂薄层的6cm平皿上,放入二氧化碳培养箱中温育1.5h,然后用SA缓冲液稀释的补体(1:10)加入,继续温育1.5h后,计数溶血空斑数。结果见表3。
*与对照组相比P<0.05
样品高剂量组小鼠抗体积数明显高于对照组,经统计,差异有统计学意义(P<0.05)。
1.3.4血清溶血素的测定:将小鼠摘除眼球采血,于2000r/min分离血清,用生理盐水将血清倍比稀释,将不同稀释度的血清分别置于微量血凝板内,每孔100μl,再加入100μl0.5%(V/V)的SRBC悬液,混匀,装入湿润的平盘内加盖,于37℃温箱孵育3h,观察血球凝集程度。结果见表4。
*与对照组相比P<0.05
结果表明,样品高剂量组小鼠抗体积数明显高于对照组,经统计,差异有统计学意义(P<0.05)。
1.3.5小鼠腹腔巨噬细胞吞噬鸡红细胞实验(半体内法)和脏器/体重比值:每鼠腹腔注射20%鸡红细胞悬液1ml,间隔30min颈椎脱臼处死动物,将其仰位固定于鼠板上,正中剪开腹壁皮肤,经腹腔注入生理盐水2ml,转动鼠板1min。然后吸出腹腔洗液1ml,平均分滴于2片载玻片上,放入垫有湿纱布的搪瓷盒内,移置37℃孵箱温育30min,孵毕,于生理盐水中漂洗,以除去未贴片细胞,晾干,以1:1丙酮甲醇溶液固定,4%(V/V)Giemsa-磷酸缓冲液冲洗染色3min,再用蒸馏水漂洗晾干,在油镜下阅片读数,计算吞噬率和吞噬指数,并解剖动物取出脾脏及胸腺,用滤纸吸干血迹后称重,并计算胸腺指数和脾指数。结果见表5。
样品各剂量组小鼠胸腺指数、脾指数与对照组相比,差异均无统计学意义(P>0.05)。
1.3.6ConA诱导的小鼠淋巴细胞转化实验和小鼠NK细胞活性测定(乳酸脱氢酶LDH测定法):颈椎脱臼法处死小鼠,无菌取脾,置于盛有适量无菌Hanks液的小平皿中,用镊子轻轻将脾撕碎,经200目筛网过滤,制成单细胞悬液,将细胞悬液分为两部分,分别用于ConA诱导的小鼠淋巴细胞转化实验和小鼠NK细胞活性测定。
1.3.6.1ConA诱导的小鼠淋巴细胞转化实验:用Hanks液洗涤细胞悬液2次,每次离心10min(1000r/min),然后将细胞悬浮于1ml的完全培养液中,台酚兰染色计数活细胞数(95%以上),调整细胞浓度为3×106个/ml,将每份细胞悬液分两孔加入24孔培养板中,每孔1ml,一孔加75μl ConA液,另一孔为对照,置培养箱中培养72h。培养结束前4h,每孔吸去上清液0.7ml,加入0.7ml不含小牛血清的RPMI1640培养液,同时加入MTT50μl/孔,继续培养4h,培养结束后,每孔加入1ml酸性异丙醇,吹打混匀,使紫色结晶完全溶解,然后分装倒入96孔培养板,每孔做3个平行孔,用酶标仪以570nm波长测定光密度值。结果见表6。
1.3.6.2小鼠NK细胞活性测定(乳酸脱氢酶LDH测定法):试验前24小时将靶细胞传代培养,用前以Hanks液洗3次,用RPMI1640完全培养液调整细胞浓度为4×105个/ml,用Hanks液洗涤脾细胞悬液2次,每次离心10min(1000r/min),弃上清液将细胞浆弹起,加入0.5ml灭菌水20秒,裂解红细胞后再加入0.5ml2倍Hanks液及8ml Hanks液,离心10min(1000r/min),用1ml完全培养液重悬,用1%冰醋酸稀释后计数,台酚兰染色计数活细胞数(应在95%以上),调整细胞浓度为2×107个/ml,取靶细胞和效应细胞各100μl(效靶比为50:1),加入96孔培养板中;靶细胞自然释放孔加靶细胞和培养液各100μl,靶细胞最大释放孔加靶细胞和1%NP40各100μl,上述各项均设三个平行孔,于37℃、5%CO2培养箱中培养4小时,然后将培养板离心(1500r/min)5min,每孔吸取上清液100μl置于96孔培养板中,同时加入LDH基质液100μl,反应3min,每孔加入1mol/L的HCl 30μl,在酶标仪490nm处测定光密度值(OD),计算NK细胞活性。结果见表7。
*与对照组相比P<0.05
样品高剂量组小鼠淋转OD差值明显高于对照组,差异有统计学意义(P<0.05)。
样品各剂量组小鼠NK细胞活性与对照品比较,差异均无统计学意义(P>0.05)。
1.4实验数据统计方法:实验数据以SPSS软件进行单因素方差分析。经方差齐性检验,方差齐的实验数据采用LSD法进行统计分析,方差不齐的实验数据采用Tambane法进行统计分析。
1.5结论
由以上结果可见,样品高剂量组明显增强ConA诱导小鼠脾淋巴细胞增殖能力,促进DNFB诱导的迟发型变态反应;明显升高血清溶血素水平,促进小鼠抗体生成细胞生成。根据《保健食品检验与评价技术规范》之辅助增强免疫力功能试验的结果判定,在本试验条件下,本实施例1的产品具有辅助增强免疫力功能。
实验例2
本实施例1制得的增强免疫力的组合物经动物急性毒性试验表明无毒副作用,其详细说明如下:
2、材料与方法
2.1样品:采用实施例1制得的产品,成人日服推荐用量为12g,相当于0.2g/kg BW/d(成人体重按60kg计算)。
2.2实验动物及环境:清洁级健康ICR小鼠。
2.3小鼠急性经口毒性试验:采用最大耐受剂量(MTD)试验法,选体重18-22g的健康ICR小鼠20只,雌雄各半。试验前小鼠隔夜禁食16小时,不禁水。称取样品10.0g,加蒸馏水至10ml,搅拌均匀,采取灌胃方式给药,按照每只小鼠每日灌胃剂量为20g/kg BW,即灌胃容量为0.02ml/g BW,灌胃后,连续观察14天,观察并记录动物中毒的表现和死亡情况。
2.4结果:给药后至第14天,各鼠的外观、行为、呼吸、四肢活动、进食、排泄等均未见明显异常;无中毒死亡现象;实验结果见表8。
表8样品急性经口毒性试验结果
从表8可见,该样品急性毒性试验结果为MTD>20g/kg、BW(相当于成人日推荐量的100倍),根据急性毒性分级属无毒级。
实验例3
将实施例1-4以及对照例1中步骤1)制得的粉末进行氮溶指数(NSI)测定:
称取1g样品,溶解于50ml的去离子水中,室温下磁力搅拌溶解1h,离心,用lowrry法测定上清液(可溶部分)的蛋白含量,采用Dumas法测定样品蛋白质含量。上清液的蛋白总含量与样品蛋白总含量的比值即为氮溶指数。氮溶指数常常用来表示大豆分离蛋白溶解度及其所含功能性大豆蛋白含量,因此本试验用氮溶指数来平价各组大豆分离蛋白溶解性。
实验例4
将实施例1~4及对照例1中步骤1)制得的粉末进行分散性及粘度测定:
60s分散度:提前准备去离子水30ml于100ml烧杯中,打开搅拌器,保持转速恒定在500r/min,称取0.5g SPI快速倒入烧杯,同时按下秒表,搅拌60s后,关闭搅拌器,迅速将悬浮液倒入60目滤网过滤,测定滤液中蛋白含量。分散度表示为滤液中蛋白质含量与总蛋白质含量的比值。滤液中蛋白质含量与总蛋白质含量均采用微量凯氏定氮法测定。
粘度测定:称取试样30.00g于500ml塑料烧杯中,倒入170ml蒸馏水,加10滴消泡剂(消泡剂∶水=2∶1),用玻璃棒搅拌30秒,将挂于烧杯壁上的试样全部溶于水中,用手持高速搅拌器低速档搅拌30秒后,在2分钟内,用数显粘度计测定其粘度,直接读取并记录。
各组试验结果如下表所示。
Claims (8)
1.一种增强免疫力的组合物,其特征在于:由大豆分离蛋白、浓缩乳清蛋白、维生素、矿物质和益生元组成,其重量比为(20~60):(10~30)(0.5~10):(0.1~2):(2~30)。
2.根据权利要求1所述的一种增强免疫力的组合物,其特征在于:所述浓缩乳清蛋白中乳铁蛋白含量>0.05%、免疫球蛋白>3%。
3.根据权利要求1所述的一种增强免疫力的组合物,其特征在于:所述维生素是由维生素C和维生素X组成,其中,维生素C占维生素总量的重量百分比>0.8%;所述维生素X选自叶酸、维生素B1、维生素B2、维生素B6和维生素B12中的一种或多种。
4.根据权利要求1所述的一种增强免疫力的组合物,其特征在于:所述矿物质是由硒剂和锌剂组成,其中,锌剂占矿物质总重百分比>0.1%;所述硒剂选自亚硒酸钠、硒蛋白和富硒食用菌粉中的一种或多种;所述锌剂选自葡萄糖酸锌、乳酸锌、柠檬酸锌和氯化锌中的一种或多种。
5.根据权利要求1所述的一种增强免疫力的组合物,其特征在于:所述益生元选自低聚木糖、低聚异麦芽糖、低聚果糖和木糖醇中的一种或多种。
6.权利要求1~5中任一项所述的增强免疫力的组合物的制备方法,其特征在于:包括以下步骤:
1)将配方量的大豆分离蛋白和浓缩乳清蛋白混合,加水溶解,在-1~-5℃下冻结1~5h,在室温条件下解冻;再置于-5~-35℃下冻结10~20h,在室温条件下解冻,干燥,粉碎过筛,备用;
2)将配方量的维生素、矿物质、益生元分别过筛,备用;
3)将步骤1)、2)的配料混匀,即得。
7.根据权利要求6所述的增强免疫力的组合物的制备方法,其特征在于:步骤1)中,水的加入量为大豆分离蛋白和浓缩乳清蛋白总重的10~25倍。
8.根据权利要求6所述的增强免疫力的组合物的制备方法,其特征在于:步骤1)、2)中所述过筛为过60目筛。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110762563.4A CN113678972A (zh) | 2021-07-06 | 2021-07-06 | 一种增强免疫力的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110762563.4A CN113678972A (zh) | 2021-07-06 | 2021-07-06 | 一种增强免疫力的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113678972A true CN113678972A (zh) | 2021-11-23 |
Family
ID=78576678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110762563.4A Pending CN113678972A (zh) | 2021-07-06 | 2021-07-06 | 一种增强免疫力的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113678972A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114586987A (zh) * | 2022-03-10 | 2022-06-07 | 山东若尧特医食品有限公司 | 一种特殊医学用途蛋白质组件配方食品及制备方法和应用 |
-
2021
- 2021-07-06 CN CN202110762563.4A patent/CN113678972A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114586987A (zh) * | 2022-03-10 | 2022-06-07 | 山东若尧特医食品有限公司 | 一种特殊医学用途蛋白质组件配方食品及制备方法和应用 |
CN114586987B (zh) * | 2022-03-10 | 2024-02-27 | 山东若尧特医食品有限公司 | 一种特殊医学用途蛋白质组件配方食品及制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5517215B2 (ja) | 発酵及び培養方法、植物発酵エキス、植物発酵エキス末並びに該植物発酵エキス配合物 | |
AU2017361526B2 (en) | Liquid allergen compositions and methods for making the same | |
CN103689296A (zh) | 妊娠后期和哺乳期的母羊饲料及其制备方法 | |
CN111990461A (zh) | 一种增强免疫力的调制乳粉及其制备方法 | |
CN109393262A (zh) | 一种胶原蛋白蔓越莓果饮及其制备方法 | |
CN110269224A (zh) | 一种接骨木果冻及其制备方法 | |
CN105410346A (zh) | 提高养殖对虾存活率的中药制剂及其制备方法 | |
RU2736055C1 (ru) | Композиция для улучшения внутреннего кровообращения и замедления старения, а также способ ее применения | |
CN107410811B (zh) | 一种叶黄素微胶囊的制备方法及叶黄素微胶囊速溶饮料 | |
CN112690450A (zh) | 解酒护肝的组合物及其制备方法和包含其的产品 | |
Tijani et al. | Studies on phytochemical, nutraceutical profiles and potential medicinal values of Allium sativum Linn (Lilliaceae) on bacterial meningitis | |
CN103710237A (zh) | 一种蜂产品酒及其制备方法 | |
CN110172106A (zh) | 一种桃胶多糖铁及其应用 | |
CN113678972A (zh) | 一种增强免疫力的组合物及其制备方法 | |
TW202019453A (zh) | 角豆樹果組合物及其製備方法與應用 | |
CN105920198B (zh) | 一种具有补血功效的细胞破壁微粉及其制备方法 | |
CN104256165A (zh) | 用于防治慢性型猪瘟疫的功能性饲料及其制备方法 | |
RU2333677C2 (ru) | Биологически активная добавка | |
KR101713115B1 (ko) | 발효 오신채 추출물을 함유하는 화장료 조성물 | |
CN108619484B (zh) | 一种护肝解酒蚕蛹提取生物蛋白 | |
CN112972540A (zh) | 一种防醉解酒保肝组合物及制备方法以及应用 | |
JP5742060B2 (ja) | ネギ属由来の成分を含む免疫賦活剤及び免疫賦活剤の製造方法 | |
JP2005097133A (ja) | ハナビラタケ由来IgA産生促進剤 | |
CN112057476B (zh) | 一种组合物及其在醒酒解宿醉护胃上的应用 | |
CN108935701A (zh) | 一种提高免疫力的羊奶粉、羊奶粉的制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |